Journal of Medicinal Chemistry p. 1421 - 1426 (1987)
Update date:2022-08-03
Topics:
Bandurco, Victor T.
Schwender, Charles F.
Bell, Stanley C.
Combs, Donald W.
Kanojia, Ramesh M.
et al.
The synthesis, cardiac fraction III cyclic nucleotide phosphodiesterase (PDE-III) inhibition, and positive inotropic activity of a series of 2(1H)-quinazolinones are reported.A general synthesis of the series involved the cyclization of 2-aminoacetophenones with potassium cyanate in acetic acid.Modifications at the 4-position of the quinazoline nucleus were best achieved by formation of the intermediate N1-acyl-N3-phenylurea from the substituted phenyl isocyanate and appropriate carboxamide.PPA was used to ring close to the quinazoline product.Generally the SAR for the series paralleled the five-point model previously published for PDE-III inhibition.The most active analogue of the series was 5,6-dimethoxy-4-methyl-2(1H)-quinazolinone (1) (ORF 16600), which had about twice the intravenous potency of amrinone.Compound 1 is currently under development as an orally active cardiotonic.
View MoreZhengzhou Yuanli Biological Technology Co., Ltd.
Contact:+86-371-67897870/67897895
Address:No. 38, Qingyang Street, Zhengzhou, Henan, China
ShangHai Ruiyi Medical Technology Co.,Ltd.
Contact:+86-21-54718086
Address:No951 Jianchuan RD,Minhang District
Zhejiang Linhai Xinhua Chemicals Factory
Contact:0086-13661858911
Address:Xunqiao Development Zone, Linhai, Zhejiang, China
Ningbo Distant Chemicals Co.,Ltd
Contact:86-574-27862490,27862438
Address:5F-3,#54 DaShaNi street,Ningbo,CHINA
Contact:+86-25-52346955
Address:199,JIANYE ROAD,NANJING,CHINA
Doi:10.1002/zaac.200700207
(2007)Doi:10.1021/ja01526a067
(1959)Doi:10.1002/chem.200801024
(2008)Doi:10.1016/j.tetlet.2008.09.028
(2008)Doi:10.1016/S0040-4039(97)00569-8
(1997)Doi:10.1016/S0960-894X(01)00154-8
(2001)